274 related articles for article (PubMed ID: 26218737)
1. A Global Perspective on Pyrazinamide Resistance: Systematic Review and Meta-Analysis.
Whitfield MG; Soeters HM; Warren RM; York T; Sampson SL; Streicher EM; van Helden PD; van Rie A
PLoS One; 2015; 10(7):e0133869. PubMed ID: 26218737
[TBL] [Abstract][Full Text] [Related]
2. Multicenter Study of the Emergence and Genetic Characteristics of Pyrazinamide-Resistant Tuberculosis in China.
Li D; Hu Y; Werngren J; Mansjö M; Zheng X; Drobniewski F; Hoffner S; Xu B
Antimicrob Agents Chemother; 2016 Sep; 60(9):5159-66. PubMed ID: 27297481
[TBL] [Abstract][Full Text] [Related]
3. Global status of phenotypic pyrazinamide resistance in
Wang Z; Tang Z; Heidari H; Molaeipour L; Ghanavati R; Kazemian H; Koohsar F; Kouhsari E
J Chemother; 2023 Nov; 35(7):583-595. PubMed ID: 37211822
[TBL] [Abstract][Full Text] [Related]
4. Underestimated pyrazinamide resistance may compromise outcomes of pyrazinamide containing regimens for treatment of drug susceptible and multi-drug-resistant tuberculosis in Tanzania.
Juma SP; Maro A; Pholwat S; Mpagama SG; Gratz J; Liyoyo A; Houpt ER; Kibiki GS; Mmbaga BT; Heysell SK
BMC Infect Dis; 2019 Feb; 19(1):129. PubMed ID: 30732572
[TBL] [Abstract][Full Text] [Related]
5. Prevalence, Transmission and Genetic Diversity of Pyrazinamide Resistance Among Multidrug-Resistant
Liu B; Su P; Hu P; Yan M; Li W; Yi S; Chen Z; Zhang X; Guo J; Wan X; Wang J; Gong D; Bai H; Wan K; Liu H; Li G; Tan Y
Infect Drug Resist; 2024; 17():403-416. PubMed ID: 38328339
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology of pyrazinamide-resistant tuberculosis in the United States, 1999-2009.
Kurbatova EV; Cavanaugh JS; Dalton T; Click ES; Cegielski JP
Clin Infect Dis; 2013 Oct; 57(8):1081-93. PubMed ID: 23840002
[TBL] [Abstract][Full Text] [Related]
7. Counting pyrazinamide in regimens for multidrug-resistant tuberculosis.
Franke MF; Becerra MC; Tierney DB; Rich ML; Bonilla C; Bayona J; McLaughlin MM; Mitnick CD
Ann Am Thorac Soc; 2015 May; 12(5):674-9. PubMed ID: 25664920
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of tuberculosis preventive treatment for contacts of patients with multidrug-resistant tuberculosis: a systematic review and meta-analysis.
Zhou G; Luo S; He J; Chen N; Zhang Y; Cai S; Guo X; Chen H; Song C
Clin Microbiol Infect; 2024 Feb; 30(2):189-196. PubMed ID: 37741621
[TBL] [Abstract][Full Text] [Related]
9. Genetic surveillance and outcomes of pyrazinamide and fluoroquinolones-resistant tuberculosis in Taiwan.
Huang HT; Lin WH; Chan TH; Jou R
J Microbiol Immunol Infect; 2023 Dec; 56(6):1236-1244. PubMed ID: 37690869
[TBL] [Abstract][Full Text] [Related]
10. Resistance to pyrazinamide in
Balay G; Abdella K; Kebede W; Tadesse M; Bonsa Z; Mekonnen M; Amare M; Abebe G
J Clin Tuberc Other Mycobact Dis; 2024 Feb; 34():100411. PubMed ID: 38222863
[TBL] [Abstract][Full Text] [Related]
11. Multidrug-resistant tuberculosis treatment adherence in migrants: a systematic review and meta-analysis.
Nellums LB; Rustage K; Hargreaves S; Friedland JS
BMC Med; 2018 Feb; 16(1):27. PubMed ID: 29466983
[TBL] [Abstract][Full Text] [Related]
12. Completeness of tuberculosis case notifications in Germany in 2013-2017: first results of an inventory study.
Domaszewska T; Karo B; Preuss U; Kollan C; Reuss A; Blank HP; Brodhun B; Hauer B; Altmann D; Fiebig L; Haas W; Perumal N
BMC Infect Dis; 2020 Oct; 20(1):766. PubMed ID: 33069210
[TBL] [Abstract][Full Text] [Related]
13. Structural and Genomic Insights Into Pyrazinamide Resistance in
Tunstall T; Phelan J; Eccleston C; Clark TG; Furnham N
Front Mol Biosci; 2021; 8():619403. PubMed ID: 34422898
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of host PARP1 contributes to the anti-inflammatory and antitubercular activity of pyrazinamide.
Krug S; Gupta M; Kumar P; Feller L; Ihms EA; Kang BG; Srikrishna G; Dawson TM; Dawson VL; Bishai WR
Nat Commun; 2023 Dec; 14(1):8161. PubMed ID: 38071218
[TBL] [Abstract][Full Text] [Related]
15. Drug Exposure and Susceptibility of Pyrazinamide Correlate with Treatment Response in Pyrazinamide-Susceptible Patients with Multidrug-Resistant Tuberculosis.
Dong S; Shao G; Davies Forsman L; Wang S; Wang S; Cao J; Bao Z; Bruchfeld J; Alffenaar JC; Liu J; Hu Y; Wu M
Pharmaceutics; 2024 Jan; 16(1):. PubMed ID: 38276514
[TBL] [Abstract][Full Text] [Related]
16. Major adverse cardiovascular events and hyperuricemia during tuberculosis treatment.
Shin HJ; Yoon JY; Na YO; Lee JK; Kho BG; Kim TO; Kim YI; Lim SC; Jeong SH; Kwon YS
PLoS One; 2023; 18(11):e0294490. PubMed ID: 37972037
[TBL] [Abstract][Full Text] [Related]
17. Chemical reactivity and bioactivity properties of pyrazinamide analogs of acetylsalicylic acid and salicylic acid using conceptual density functional theory.
Villagracia AR; Ong HL; Lagua FM; Alea G
Heliyon; 2020 Jun; 6(6):e04239. PubMed ID: 32613118
[TBL] [Abstract][Full Text] [Related]
18. Mycobacterium tuberculosis pncA Polymorphisms That Do Not Confer Pyrazinamide Resistance at a Breakpoint Concentration of 100 Micrograms per Milliliter in MGIT.
Whitfield MG; Warren RM; Streicher EM; Sampson SL; Sirgel FA; van Helden PD; Mercante A; Willby M; Hughes K; Birkness K; Morlock G; van Rie A; Posey JE
J Clin Microbiol; 2015 Nov; 53(11):3633-5. PubMed ID: 26292310
[TBL] [Abstract][Full Text] [Related]
19. Pyrazinamide resistance in Mycobacterium tuberculosis: Review and update.
Njire M; Tan Y; Mugweru J; Wang C; Guo J; Yew W; Tan S; Zhang T
Adv Med Sci; 2016 Mar; 61(1):63-71. PubMed ID: 26521205
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of pyrazinamide resistance across the spectrum of drug resistant phenotypes of Mycobacterium tuberculosis.
Whitfield MG; Streicher EM; Dolby T; Simpson JA; Sampson SL; Van Helden PD; Van Rie A; Warren RM
Tuberculosis (Edinb); 2016 Jul; 99():128-130. PubMed ID: 27450014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
